November 20, 2026
Breaking
Business

Strand eyes US, Southeast Asia mkts for blood-based cancer screening test

admin1 min read

Reliance-backed genomics company is pursuing US FDA approval for CancerSpot and aims to cut its price in India to below ₹10,000 over the next two to three years.

The post Strand eyes US, Southeast Asia mkts for blood-based cancer screening test appeared first on Home Page.

Leave a Comment

Your email address will not be published. Required fields are marked *